Who Supplies Sitagliptin to India from SINGAPORE

To import finished pharmaceutical formulations containing Sitagliptin into India, the importing company must obtain an Importer License from the Directorate General of Foreign Trade (DGFT). Additionally, the product must be registered with the Central Drugs Standard Control Organisation (CDSCO). This involves submitting Form 40/41, along with the necessary documentation, including a No Objection Certificate (NOC) from the manufacturer. The registration process typically takes 6 to 12 months, depending on the completeness of the application and the regulatory review process. Sitagliptin formulations under HS Code 30049099 are subject to these requirements to ensure compliance with Indian pharmaceutical standards.

Imported Sitagliptin formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to ICH Zone IV guidelines, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Port inspections by customs drug inspectors are conducted to verify the authenticity and quality of the imported products. These measures ensure that imported Sitagliptin formulations meet the safety and efficacy standards mandated by Indian regulations.

Between 2024 and 2026, the CDSCO has implemented regulatory updates affecting the import of finished pharmaceutical formulations, including Sitagliptin. The Production Linked Incentive (PLI) scheme has been introduced to encourage domestic manufacturing, potentially impacting the volume of finished formulation imports. Bilateral agreements between India and Singapore have facilitated smoother trade relations, including mutual recognition of Good Manufacturing Practices (GMP), which may streamline the import process for Singaporean manufacturers. These developments aim to balance the promotion of domestic production with the need for high-quality imported pharmaceuticals.

India imports finished Sitagliptin formulations to meet the demand for patented and branded products, as well as specific dosage forms not produced domestically. The domestic capacity for Sitagliptin formulations is limited, leading to a reliance on imports to fulfill market needs. The market size for Sitagliptin formulations in India is substantial, driven by the growing prevalence of type 2 diabetes and the need for effective management options.

The import duty structure for Sitagliptin formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, an Education Cess of 2%, a Secondary Higher Education Cess of 1%, and a Countervailing Duty (CVD) of 6%. The total duty amounts to 17.10%. Additionally, the Social Welfare Surcharge (SWS) is 10%, and the Integrated Goods and Services Tax (IGST) is 12%. These duties and taxes contribute to the total landed cost of imported Sitagliptin formulations.

India sources Sitagliptin formulations from Singapore due to the country's competitive advantages, including adherence to international quality standards, advanced manufacturing technologies, and compliance with global regulatory requirements. Singaporean manufacturers offer patented formulations and specialized dosage forms that may not be available from other suppliers. While other countries like China, Germany, and the United States also supply Sitagliptin formulations, Singapore's strategic location, robust trade agreements with India, and established reputation in the pharmaceutical industry make it a preferred source.

India imports Sitagliptin formulations from Singapore due to the availability of patented formulations, specialized dosage forms, and technology-licensed products that are not produced domestically. Singaporean manufacturers offer high-quality products that meet international standards, ensuring efficacy and safety. The strategic location of Singapore and its established trade relations with India further facilitate efficient sourcing.

When compared to other origins such as China, the European Union, and the United States, Singapore offers competitive advantages in terms of quality, regulatory compliance, and reliability. Singaporean manufacturers adhere to stringent international quality standards and have a reputation for timely deliveries. While other countries may offer lower prices, Singapore's consistent quality and compliance with global regulatory requirements make it a preferred source for Sitagliptin formulations.

Indian importers face several supply chain risks when sourcing Sitagliptin formulations from Singapore, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider dual-sourcing strategies, maintain adequate inventory levels, and establish strong relationships with multiple suppliers. Regular monitoring of regulatory developments and market conditions is also essential to anticipate and address potential disruptions.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source and mitigate supply chain risks.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against potential supply disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP), to manage financial risks.
4. 4Minimum Order Quantities (MOQs): Clarify MOQs with suppliers to ensure alignment with demand forecasts and inventory management.
5. 5Supplier Qualification: Conduct thorough due diligence on suppliers, including audits of manufacturing facilities, to ensure compliance with quality standards and regulatory requirements.

1. 1DGFT Importer License: Obtain an Importer License from the Directorate General of Foreign Trade.
2. 2CDS